Apply for Kesimpta (ofatumumab) Copay Assistance & Patient Savings | QuickRx

Kesimpta copay assistance refers to financial support programs—such as manufacturer copay cards, patient assistance programs, and nonprofit MS foundation grants—that help reduce the out-of-pocket cost of Kesimpta (ofatumumab) for eligible patients. QuickRx Specialty Pharmacy provides free enrollment support to help you identify and apply for programs you may qualify for based on your insurance and financial situation. Our patient navigators handle the paperwork so you can focus on your treatment.

Eligibility for Kesimpta copay assistance varies by program. Manufacturer copay card programs are generally available to patients with commercial (private) insurance. Patient assistance programs are typically available to patients who are uninsured, underinsured, or whose government insurance (such as Medicare or Medicaid) does not cover the copay card benefit.

QuickRx evaluates your specific insurance situation to identify the programs you are most likely to qualify for and manages all enrollment at no cost to you.

No. QuickRx Specialty Pharmacy provides copay assistance enrollment support as a completely free service. There are no fees, no hidden charges, and no obligation. Our patient navigator team assists with your Kesimpta application because we believe cost should never be a barrier to MS treatment.

What QuickRx Does For Free:

• Reviews your insurance coverage and identifies all available programs
• Completes copay card and patient assistance applications on your behalf
• Coordinates with your neurologist or prescriber for required documentation
• Manages ongoing renewals and insurance changes
• Provides continuous support throughout your Kesimpta treatment

Medicare patients cannot use manufacturer copay cards due to federal regulations. However, other financial assistance options may still be available for Kesimpta.

Options for Medicare Patients:

• Patient assistance programs: May provide Kesimpta at reduced or no cost for qualifying patients
• MS-specific foundation grants: Some nonprofit MS organizations provide financial assistance regardless of insurance type
• Medicare Extra Help / Low-Income Subsidy: May help with prescription drug costs for qualifying patients
• State pharmaceutical assistance programs: Varies by state

QuickRx patient navigators can review your specific coverage and identify all available options. Call (917) 830-2525 to speak with our team.

Getting started is easy. You can apply by completing the secure form on this page or by calling our patient navigator team directly at (917) 830-2525.

Our Process:

• Step 1 — Contact Us: Call or complete our online form to get started
• Step 2 — Program Identification: Our patient navigators verify your insurance and identify all available copay cards, patient assistance programs, and foundation grants
• Step 3 — Application Submission: We complete and submit all applications on your behalf, coordinating with your prescriber for any required documentation
• Step 4 — Ongoing Support: We manage renewals, handle insurance changes, and support continuous access to your Kesimpta

All services are completely free to patients.

Kesimpta (ofatumumab) is a prescription monoclonal antibody approved by the FDA for the treatment of relapsing forms of multiple sclerosis (MS) in adults. This includes clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS.

Key Facts About Kesimpta:

• Drug class: Anti-CD20 monoclonal antibody
• How it works: Targets and depletes CD20-positive B-cells, which are believed to contribute to the inflammatory process in MS
• FDA approval date: October 26, 2009 (ofatumumab); Kesimpta approved for MS
• Form: Subcutaneous injection via Sensoready autoinjector pen or prefilled syringe (20 mg/0.4 mL)
• Available as generic: No

Kesimpta is administered as a subcutaneous (under the skin) self-injection using the Kesimpta Sensoready autoinjector pen or prefilled syringe. It is injected into the abdomen, thigh, or outer upper arm. Patients should avoid areas where the skin is tender, bruised, red, scaly, or hard, as well as moles, scars, or stretch marks.

Important Administration Notes:

• The first injection should be performed under the supervision of a qualified healthcare professional
• Before injecting, allow the Sensoready pen or prefilled syringe to reach room temperature for approximately 15 to 30 minutes — do not remove the needle cover during this time
• Each pen or syringe is for one-time use only; discard after use
• If a dose is missed, administer as soon as possible without waiting until the next scheduled dose

Always follow your neurologist’s or healthcare provider’s specific instructions for administering Kesimpta.

The Kesimpta dosing schedule consists of an initial loading phase followed by monthly maintenance injections.

Kesimpta Dosing Schedule (Adults):

• Initial phase: 20 mg injected subcutaneously once weekly for 3 doses (weeks 0, 1, and 2)
• Maintenance phase: 20 mg injected subcutaneously once monthly, beginning at week 4

Patients should follow the dosing schedule prescribed by their healthcare provider. If a dose is missed, it should be administered as soon as possible. Always consult your prescriber before making any changes to your dosing schedule.

Proper storage of Kesimpta is important to maintain medication integrity.

Kesimpta Storage Instructions:

• Store Kesimpta Sensoready pens and prefilled syringes in the refrigerator at 36°F to 46°F (2°C to 8°C) in their original container
• Do not freeze and do not shake
• Protect from light
• If needed, Kesimpta may be stored at room temperature up to 86°F (30°C) for up to 7 days; unused pens or syringes may be returned to the refrigerator and used within the next 7 days
• Discard if not used within 7 days of removing from the refrigerator at room temperature

If you have questions about storing your Kesimpta, contact your QuickRx pharmacist at (917) 830-2525.

The most commonly reported side effects of Kesimpta in MS clinical studies include upper respiratory tract infections and injection site reactions.

Common Side Effects (MS Indication):

• Upper respiratory tract infections (approximately 39%)
• Injection site reactions — systemic (approximately 21%; may include chills, fatigue, fever, or muscle aches)
• Injection site reactions — local (approximately 11%; may include redness, itching, pain, or swelling at the injection site)
• Headache (approximately 13%)
• Urinary tract infections (approximately 10%)

This is not a complete list of side effects. Talk to your healthcare provider if you experience any side effects that concern you or do not go away.

Yes. Kesimpta carries important warnings that patients should discuss with their neurologist or prescriber before starting treatment.

Important Kesimpta Warnings:

• Serious infections: Kesimpta increases the risk of serious bacterial, fungal, and viral infections. Patients with active infections should delay starting treatment until the infection has resolved
• Hepatitis B reactivation: Patients must be screened for hepatitis B before starting Kesimpta. Active hepatitis B infection is a contraindication
• Injection-related and hypersensitivity reactions: Including rare but serious anaphylaxis and angioedema
• Decreased immunoglobulin levels: Kesimpta may reduce immunoglobulin levels, which can affect the body’s ability to fight infections
• Progressive multifocal leukoencephalopathy (PML): A serious brain infection associated with CD20-directed therapies, though no PML cases were reported in Kesimpta MS clinical studies
• Liver injury: Significant liver injury has been reported; baseline liver function tests are recommended

This information is for educational purposes only. Patients should review all risks and precautions thoroughly with their prescribing healthcare provider before starting Kesimpta.

Because Kesimpta affects B-cells and may reduce the immune response to vaccines, timing of vaccinations is important.

Vaccination Guidelines for Kesimpta Patients:

• Complete all live or live-attenuated vaccines at least 4 weeks before starting Kesimpta
• Complete all non-live (inactivated) vaccines at least 2 weeks before starting Kesimpta
• Live and live-attenuated vaccines are not recommended during Kesimpta treatment or until B-cell levels have recovered after stopping treatment
• Patients should discuss their full vaccination history with their healthcare provider before starting Kesimpta

Always consult your neurologist or prescriber regarding vaccinations while on Kesimpta therapy.

Patients who can become pregnant should use effective contraception during Kesimpta therapy and for 6 months after the last dose. Data on the use of Kesimpta during pregnancy are limited.

Pregnancy Considerations:

In general, disease-modifying therapies for MS are not initiated during pregnancy. Based on data from animal studies and experience with other anti-CD20 antibodies, transient B-cell depletion and reduced lymphocyte levels may occur in newborns exposed to ofatumumab in utero. Patients who are pregnant or planning to become pregnant should discuss the risks and benefits of Kesimpta therapy thoroughly with their healthcare provider.

Breastfeeding Considerations:

It is not known whether ofatumumab is present in human milk. The decision to breastfeed during Kesimpta therapy should consider the potential risk to the infant and the benefits of treatment to the mother, in consultation with a healthcare provider.

Yes. Kesimpta may interact with other medications, particularly those that affect the immune system. Always inform your healthcare provider and pharmacist about all medications, supplements, and vaccines you are taking or planning to take.

Notable Drug Interaction Categories:

• Other immunosuppressants: Combining Kesimpta with other immunosuppressive therapies (such as corticosteroids, methotrexate, or other biologics) may increase the risk of serious infections
• Live vaccines: Should not be administered during Kesimpta treatment (see vaccine FAQ above)
• COVID-19 vaccines: Timing with Kesimpta dosing is important to optimize vaccine effectiveness; discuss timing with your neurologist
• Other MS disease-modifying therapies: Concurrent use with other immunosuppressive MS therapies is generally not recommended

QuickRx pharmacists perform thorough drug interaction reviews as part of the dispensing process. Call us at (917) 830-2525 with any questions.

Yes. QuickRx Specialty Pharmacy is licensed to dispense and ship Kesimpta to patients in all 50 states. We provide free home delivery and ensure that temperature-sensitive specialty medications like Kesimpta are shipped under appropriate conditions to maintain integrity.

Why Patients Choose QuickRx for Kesimpta:

• Nationwide shipping to all 50 states
• Free copay assistance enrollment services
• Dedicated MS patient navigators available to answer your questions
• Prior authorization support and appeal assistance
• URAC- and ACHC-accredited specialty pharmacy
• HIPAA-compliant intake and enrollment process

Call us at (917) 830-2525 or complete the form on this page to get started.

QuickRx is a URAC- and ACHC-accredited specialty pharmacy with a dedicated MS patient navigator team and hands-on financial support services.

What Sets QuickRx Apart:

• Dedicated MS patient navigators who specialize in complex specialty medication access
• Free copay card enrollment, patient assistance applications, and foundation grant coordination
• Prior authorization management and appeals support
• Licensed in all 50 states with free home delivery
• URAC- and ACHC-accredited — held to the highest standards in specialty pharmacy
• Personal, one-on-one support from enrollment through ongoing treatment

Our goal is to make sure no MS patient goes without their Kesimpta due to cost. Complete the form above or call us at (917) 830-2525 to get started today.